Physician profile

Mary Chambers

Pediatrics · Columbus, IN

NPI 1124027438

$369.81

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$30.64

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $87.57 2019-2020
Ironshore Pharmaceuticals INC. $72.08 2019-2020
Adlon Therapeutics L.P. $48.52 2019-2020
Tris Pharma INC $47.80 2019-2020
Sanofi Pasteur INC. $39.42 2020-2023
Novo Nordisk INC $17.06 2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $15.46 2019
Glaxosmithkline, LLC. $14.72 2020
Novartis Pharmaceuticals Corporation $14.56 2020
Corium, LLC $12.62 2023 Azstarys

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mary Chambers

$369.81

in general payments reported 2019-2025

Years
2019-2023
Top company
Takeda Pharmaceuticals U.S.A., INC.

https://glasscript.com/doctor/565797/mary-chambers

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.